Filing summary
Entity mismatch: The supplied metadata names PALVELLA THERAPEUTICS, INC., but the filing identifies the registrant as PIERIS PHARMACEUTICALS, INC. This summary reflects the Pieris filing; verify that it is the intended company.
Business context and reporting period
This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2018. Pieris is a clinical-stage biopharmaceutical company developing Anticalin-based medicines. It has no product-sales revenue; revenue primarily comes from collaborations and licenses. Key programs include PRS-060 for asthma, PRS-343 in immuno-oncology, and PRS-080 for anemia.
Financial performance and position
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Revenue | $8.3 million | $3.9 million | $24.2 million | $7.1 million |
| Research and development expense | $11.4 million | $6.3 million | $28.5 million | $17.0 million |
| General and administrative expense | $4.7 million | $2.9 million | $13.9 million | $11.2 million |
| Net loss | $6.2 million | $7.1 million | $15.1 million | $25.1 million |
| Net loss per share | $0.11 | $0.16 | $0.29 | $0.58 |
- At September 30, 2018, cash and cash equivalents were $89.5 million and short-term investments were $47.8 million, or $137.3 million combined. Total current assets were $146.8 million and current liabilities were $40.6 million.
- Cash provided by operating activities was $8.0 million for the first nine months, versus $54.4 million in 2017. Investing activities used $3.7 million; financing activities provided $48.5 million, primarily from the February 2018 stock offering.
- Total liabilities were $101.4 million, including $92.7 million of deferred revenue. The balance sheet does not show a separate debt balance; the company notes that it had received $6.5 million from loans historically.
- Gross profit or operating margins are not separately presented. Pieris reported an operating loss of $18.2 million for the first nine months of 2018, compared with $21.1 million in 2017.
Material changes versus the prior comparable period
- Nine-month revenue increased $17.1 million, mainly from collaboration and license revenue involving AstraZeneca, Servier, and Seattle Genetics. Seattle Genetics contributed $4.5 million and AstraZeneca $14.8 million during the period.
- Nine-month operating expenses rose $14.2 million, with R&D expense up $11.5 million. Pieris attributed the increase primarily to PRS-343 clinical activity, other immuno-oncology program work, PRS-060 clinical costs, and increased staffing and laboratory expenses.
- The net loss narrowed year over year despite higher operating expenses, reflecting higher collaboration revenue and improved non-operating results, including foreign-exchange gains and investment interest income.
- Financing cash flow included $47.2 million of net proceeds from the February public offering. The company issued 6.325 million shares at $8.00 per share; common shares outstanding rose to 54.15 million from 45.02 million at year-end 2017.
Outlook, risks, and unusual items
- Management stated that available cash, cash equivalents, and investments were expected to fund operating and capital requirements for at least 12 months from the financial-statement issuance date. Pieris expects substantial losses and rising development costs for the next several years and may need additional capital.
- PRS-060’s Phase I multiple-ascending-dose study was ongoing. PRS-343 dose escalation continued, with initial data expected in the first half of 2019; data from its combination trial with atezolizumab were also expected in 2019. Pieris planned two new immuno-oncology IND filings in 2019.
- For PRS-080, the filing reported iron mobilization and increased transferrin saturation, but no conclusive hemoglobin change versus placebo. The company planned to complete dosing by year-end 2018 and report the full data set in the first half of 2019.
- Potential milestone payments under existing partnerships are substantial but contingent: up to $2.887 billion in research, development, and commercial milestones and $2.321 billion in sales milestones. These amounts are not guaranteed revenue.
- Discussions to revise the Technical University of Munich license could increase obligations by up to $2.7 million for 2017–2018 sublicensing activity. The company said this amount would be recorded as additional R&D expense when probable and estimable.
- A post-quarter German office and laboratory lease was signed October 24, 2018. It provides for approximately $0.2 million monthly base rent for the initial 105,057 square feet, with phased delivery and an initial 150-month term; the agreement is contingent on building permits. Pieris guarantees the lease.
- Management concluded disclosure controls were not effective as of September 30, 2018 because of a previously reported material weakness in the financial-statement close process, involving expense classification and foreign-currency remeasurement. Remediation was ongoing.
- Other significant risks include clinical and regulatory uncertainty, dependence on collaboration partners, foreign-currency exposure, and potential dilution or unfavorable financing terms. The filing reported no material pending legal proceedings and no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm the registrant identity: the filing is for Pieris Pharmaceuticals, not the company named in the request metadata.
- Review collaboration revenue timing, partner concentration, deferred-revenue balances, and the conditions attached to potential milestone payments.
- Assess whether the stated 12-month cash runway remains adequate given planned clinical and preclinical spending and the possibility of additional financing.
- Track clinical results and timing for PRS-060, PRS-343, and PRS-080, including whether stated data and IND timelines are achieved.
- Monitor resolution of the TUM license discussions, the German lease commitments, and remediation of the material weakness in internal controls.